GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLEW) » Definitions » Accounts Payable

ISLEW (Isleworth Healthcare Acquisition) Accounts Payable : $0.13 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Isleworth Healthcare Acquisition Accounts Payable?

Isleworth Healthcare Acquisition's Accounts Payable for the quarter that ended in Jun. 2022 was $0.13 Mil.

Isleworth Healthcare Acquisition's quarterly Accounts Payable stayed the same from Dec. 2021 ($0.00 Mil) to Mar. 2022 ($0.00 Mil) but then increased from Mar. 2022 ($0.00 Mil) to Jun. 2022 ($0.13 Mil).

Isleworth Healthcare Acquisition Accounts Payable Historical Data

The historical data trend for Isleworth Healthcare Acquisition's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isleworth Healthcare Acquisition Accounts Payable Chart

Isleworth Healthcare Acquisition Annual Data
Trend Dec20 Dec21
Accounts Payable
- -

Isleworth Healthcare Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Accounts Payable Get a 7-Day Free Trial - - - - 0.13

Isleworth Healthcare Acquisition Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Isleworth Healthcare Acquisition Accounts Payable Related Terms

Thank you for viewing the detailed overview of Isleworth Healthcare Acquisition's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Isleworth Healthcare Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Isleworth Healthcare Acquisition Corp (NAS:ISLEW) » Definitions » Accounts Payable
Comparable Companies
AVAC TRCA IFIN WAVC IQMD FRW SHCA OCA BIOT DWIN GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
360 Central Avenue, First Central Tower, Suite No. 800, Saint Petersburg, FL, USA, 33701
Website
https://www.isleworthhealthcare.com
Isleworth Healthcare Acquisition Corp is a blank check company.

Isleworth Healthcare Acquisition Headlines

From GuruFocus

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-10-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 06-05-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 05-18-2022

Isleworth Healthcare Acquisition Corp. Announces Cancellation of Special Meeting of Shareholders, Redemption of Public Shares and Subsequent Dissolution

By PRNewswire PRNewswire • 08-25-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-26-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 06-20-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 07-05-2022

Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

By PRNewswire PRNewswire • 05-06-2022

Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK� Cell Engager antibody at EHA 2022 Congress

By PRNewswire PRNewswire • 07-10-2022

Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK� Cell Engager at EHA 2022 Congress

By PRNewswire PRNewswire • 06-27-2022